spacer
home > pmps > winter 2003 > dry powder inhalers - the best alternative drug delivery method?
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Dry Powder Inhalers - The Best Alternative Drug Delivery Method?

Delivering drugs directly to the lungs has long been known to have particular benefits for treating pulmonary conditions such as asthma and chronic obstructive pulmonary disease (COPD). By delivering drugs straight to the diseased tissues it is possible to improve the effectiveness of the treatment whilst minimising the drug side effects. Recently, efforts have been made to use the pulmonary drug delivery route to treat a wider range of conditions, including non-pulmonary conditions such as diabetes. However, despite the fact that the average human breathes 25 times every minute, successfully delivering repeatable levels of drug deep into the lungs is a significant challenge.

For a drug particle to have a reasonable chance of being inhaled it needs to have an aerodynamic diameter smaller than five microns and it needs to be inhaled by the patient at the start of their inhalation. Larger particles will end up remaining in the patient's mouth or on the back of their throat, and particles inhaled at the end of the patient's inhalation stroke will remain in the entrance to the lungs or will be exhaled.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Jon Tuckwell, Head of Drug Delivery at Cambridge Consultants

Jon Tuckwell is Head of the drug delivery business at Cambridge Consultants. Jon's experience includes working on a wide variety of drug delivery devices including needleless injectors, micro-infusion pumps and five pulmonary inhalers. In the last year Jon has led teams of engineers and scientists to develop two novel MDI technologies designed to overcome the common challenges with pMDIs. Jon has a Masters degree in Mechanical Engineering from Cambridge University.

spacer
Jon Tuckwell
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Arcis Biotechnology appointments Professor Steve Howell as Non-Executive Chairman

Daresbury, UK, 24 July 2019: Arcis Biotechnology (“Arcis”), the nucleic acid sample preparation solution provider, today announced it has appointed Professor Steve Howell as Non-Executive Chairman of its Board of Directors. Steve takes over the position from Paul Foulger, who was serving as Chairman on an interim basis on behalf of the Board.
More info >>

White Papers

The Importance of ADCC in Assessing Clinically Relevant Differences

Sartorius Stedim BioOutsource Ltd

Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more about these molecules.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement